Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4
Comparing the efficacy of peginterferon alpha-2b plus ribavirin with interferon alpha -2b plus ribavirin in Saudi patients with chronic hepatitis C virus (HCV) commonly infected with genotype 4. A total of 96 patients with chronic HCV infection were randomly assigned to two treatment groups. Forty-e...
Gespeichert in:
| Veröffentlicht in: | Liver international 2004-12, Vol.24 (6), p.568-574 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 574 |
|---|---|
| container_issue | 6 |
| container_start_page | 568 |
| container_title | Liver international |
| container_volume | 24 |
| creator | Alfaleh, F Z Hadad, Q Khuroo, M S Aljumah, A Algamedi, A Alashgar, H Al-Ahdal, M N Mayet, I Khan, M Q Kessie, G |
| description | Comparing the efficacy of peginterferon alpha-2b plus ribavirin with interferon alpha -2b plus ribavirin in Saudi patients with chronic hepatitis C virus (HCV) commonly infected with genotype 4.
A total of 96 patients with chronic HCV infection were randomly assigned to two treatment groups. Forty-eight patients received once weekly 100 microg of peginterferon alpha-2b plus ribavirin given orally 800 mg/day (peginterferon group). Another 48 patients received thrice weekly 3 million units of interferon alpha-2b plus ribavirin 800 mg/day (interferon group). At the end of treatment (48 weeks) and sustained (72 weeks) biochemical and virologic responses were determined.
In the peginterferon group, 70.8% (34/48) patients attained both biochemical and virologic responses at the end of the treatment as against 52.1% (25/48) patients in the interferon group. (P=0.09 for both). Similarly, sustained biochemical and virologic responses in the peginterferon group were attained in 52.1% (25/48) and 43.8% (21/48) patients as against 43.8% (21/48) and 29.2% (14/48) patients in the interferon group, respectively (P=0.54 and 0.20, respectively). The sustained virologic response rates in patients with genotype 4 were 42.9% (12/28) in the peginterferon group and 32.3% (10/31) in the interferon group (P=0.43). Patients in peginterferon group had higher, although statistically not significant adverse reactions.
Saudi patients with chronic HCV attained a higher, although statistically not significant sustained virologic response with pegylated interferon plus ribavirin compared with interferon plus ribavirin. |
| doi_str_mv | 10.1111/j.1478-3231.2004.0976.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67135072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67135072</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-30d83ee692ffe751217dee52c3fd2662fe185cf35bd77e1a6a6237a628908f423</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRb0A0VL4BfCKXYIfsZ0sUcVLqgQSsI6cZNy6ygvbAfpl_B6uKHtmMSPdOXeuNAhdUpLSWNfblGYqTzjjNGWEZCkplEy_jtD8oDM-Q6febwmhRSHoCZpRIaQURM7R9zOsbR_AGXBDj3U7bnTCKjy2k8fOVvrDOtvjeuhG7aDBnzZs8D8MZnARs8HqFgcHOnTQBzwYXG-izdZ4A6MOce_xMoL4RU-NxXspcn6f1w19u4srA3X4C15DP4TdCDg7Q8dGtx7OD3OB3u5uX5cPyerp_nF5s0pGyouQcNLkHEAWzBhQgjKqGgDBam4aJiUzQHNRGy6qRimgWmrJuIotL0huMsYX6Or37uiG9wl8KDvra2hb3cMw-VIqygVRe_DiAE5VB005Ottptyv_Xs1_AHLZhMM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67135072</pqid></control><display><type>article</type><title>Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Alfaleh, F Z ; Hadad, Q ; Khuroo, M S ; Aljumah, A ; Algamedi, A ; Alashgar, H ; Al-Ahdal, M N ; Mayet, I ; Khan, M Q ; Kessie, G</creator><creatorcontrib>Alfaleh, F Z ; Hadad, Q ; Khuroo, M S ; Aljumah, A ; Algamedi, A ; Alashgar, H ; Al-Ahdal, M N ; Mayet, I ; Khan, M Q ; Kessie, G</creatorcontrib><description>Comparing the efficacy of peginterferon alpha-2b plus ribavirin with interferon alpha -2b plus ribavirin in Saudi patients with chronic hepatitis C virus (HCV) commonly infected with genotype 4.
A total of 96 patients with chronic HCV infection were randomly assigned to two treatment groups. Forty-eight patients received once weekly 100 microg of peginterferon alpha-2b plus ribavirin given orally 800 mg/day (peginterferon group). Another 48 patients received thrice weekly 3 million units of interferon alpha-2b plus ribavirin 800 mg/day (interferon group). At the end of treatment (48 weeks) and sustained (72 weeks) biochemical and virologic responses were determined.
In the peginterferon group, 70.8% (34/48) patients attained both biochemical and virologic responses at the end of the treatment as against 52.1% (25/48) patients in the interferon group. (P=0.09 for both). Similarly, sustained biochemical and virologic responses in the peginterferon group were attained in 52.1% (25/48) and 43.8% (21/48) patients as against 43.8% (21/48) and 29.2% (14/48) patients in the interferon group, respectively (P=0.54 and 0.20, respectively). The sustained virologic response rates in patients with genotype 4 were 42.9% (12/28) in the peginterferon group and 32.3% (10/31) in the interferon group (P=0.43). Patients in peginterferon group had higher, although statistically not significant adverse reactions.
Saudi patients with chronic HCV attained a higher, although statistically not significant sustained virologic response with pegylated interferon plus ribavirin compared with interferon plus ribavirin.</description><identifier>ISSN: 1478-3223</identifier><identifier>DOI: 10.1111/j.1478-3231.2004.0976.x</identifier><identifier>PMID: 15566506</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Genotype ; Hepatitis C, Chronic - diagnosis ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - genetics ; Humans ; Interferon-alpha - administration & dosage ; Liver Function Tests ; Male ; Middle Aged ; Polyethylene Glycols ; Probability ; Recombinant Proteins ; Ribavirin - administration & dosage ; Risk Assessment ; RNA, Viral ; Saudi Arabia ; Severity of Illness Index ; Statistics, Nonparametric ; Treatment Outcome</subject><ispartof>Liver international, 2004-12, Vol.24 (6), p.568-574</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15566506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alfaleh, F Z</creatorcontrib><creatorcontrib>Hadad, Q</creatorcontrib><creatorcontrib>Khuroo, M S</creatorcontrib><creatorcontrib>Aljumah, A</creatorcontrib><creatorcontrib>Algamedi, A</creatorcontrib><creatorcontrib>Alashgar, H</creatorcontrib><creatorcontrib>Al-Ahdal, M N</creatorcontrib><creatorcontrib>Mayet, I</creatorcontrib><creatorcontrib>Khan, M Q</creatorcontrib><creatorcontrib>Kessie, G</creatorcontrib><title>Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Comparing the efficacy of peginterferon alpha-2b plus ribavirin with interferon alpha -2b plus ribavirin in Saudi patients with chronic hepatitis C virus (HCV) commonly infected with genotype 4.
A total of 96 patients with chronic HCV infection were randomly assigned to two treatment groups. Forty-eight patients received once weekly 100 microg of peginterferon alpha-2b plus ribavirin given orally 800 mg/day (peginterferon group). Another 48 patients received thrice weekly 3 million units of interferon alpha-2b plus ribavirin 800 mg/day (interferon group). At the end of treatment (48 weeks) and sustained (72 weeks) biochemical and virologic responses were determined.
In the peginterferon group, 70.8% (34/48) patients attained both biochemical and virologic responses at the end of the treatment as against 52.1% (25/48) patients in the interferon group. (P=0.09 for both). Similarly, sustained biochemical and virologic responses in the peginterferon group were attained in 52.1% (25/48) and 43.8% (21/48) patients as against 43.8% (21/48) and 29.2% (14/48) patients in the interferon group, respectively (P=0.54 and 0.20, respectively). The sustained virologic response rates in patients with genotype 4 were 42.9% (12/28) in the peginterferon group and 32.3% (10/31) in the interferon group (P=0.43). Patients in peginterferon group had higher, although statistically not significant adverse reactions.
Saudi patients with chronic HCV attained a higher, although statistically not significant sustained virologic response with pegylated interferon plus ribavirin compared with interferon plus ribavirin.</description><subject>Adult</subject><subject>Aged</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Genotype</subject><subject>Hepatitis C, Chronic - diagnosis</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - genetics</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Liver Function Tests</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Polyethylene Glycols</subject><subject>Probability</subject><subject>Recombinant Proteins</subject><subject>Ribavirin - administration & dosage</subject><subject>Risk Assessment</subject><subject>RNA, Viral</subject><subject>Saudi Arabia</subject><subject>Severity of Illness Index</subject><subject>Statistics, Nonparametric</subject><subject>Treatment Outcome</subject><issn>1478-3223</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRb0A0VL4BfCKXYIfsZ0sUcVLqgQSsI6cZNy6ygvbAfpl_B6uKHtmMSPdOXeuNAhdUpLSWNfblGYqTzjjNGWEZCkplEy_jtD8oDM-Q6febwmhRSHoCZpRIaQURM7R9zOsbR_AGXBDj3U7bnTCKjy2k8fOVvrDOtvjeuhG7aDBnzZs8D8MZnARs8HqFgcHOnTQBzwYXG-izdZ4A6MOce_xMoL4RU-NxXspcn6f1w19u4srA3X4C15DP4TdCDg7Q8dGtx7OD3OB3u5uX5cPyerp_nF5s0pGyouQcNLkHEAWzBhQgjKqGgDBam4aJiUzQHNRGy6qRimgWmrJuIotL0huMsYX6Or37uiG9wl8KDvra2hb3cMw-VIqygVRe_DiAE5VB005Ottptyv_Xs1_AHLZhMM</recordid><startdate>200412</startdate><enddate>200412</enddate><creator>Alfaleh, F Z</creator><creator>Hadad, Q</creator><creator>Khuroo, M S</creator><creator>Aljumah, A</creator><creator>Algamedi, A</creator><creator>Alashgar, H</creator><creator>Al-Ahdal, M N</creator><creator>Mayet, I</creator><creator>Khan, M Q</creator><creator>Kessie, G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200412</creationdate><title>Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4</title><author>Alfaleh, F Z ; Hadad, Q ; Khuroo, M S ; Aljumah, A ; Algamedi, A ; Alashgar, H ; Al-Ahdal, M N ; Mayet, I ; Khan, M Q ; Kessie, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-30d83ee692ffe751217dee52c3fd2662fe185cf35bd77e1a6a6237a628908f423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Genotype</topic><topic>Hepatitis C, Chronic - diagnosis</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - genetics</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Liver Function Tests</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Polyethylene Glycols</topic><topic>Probability</topic><topic>Recombinant Proteins</topic><topic>Ribavirin - administration & dosage</topic><topic>Risk Assessment</topic><topic>RNA, Viral</topic><topic>Saudi Arabia</topic><topic>Severity of Illness Index</topic><topic>Statistics, Nonparametric</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alfaleh, F Z</creatorcontrib><creatorcontrib>Hadad, Q</creatorcontrib><creatorcontrib>Khuroo, M S</creatorcontrib><creatorcontrib>Aljumah, A</creatorcontrib><creatorcontrib>Algamedi, A</creatorcontrib><creatorcontrib>Alashgar, H</creatorcontrib><creatorcontrib>Al-Ahdal, M N</creatorcontrib><creatorcontrib>Mayet, I</creatorcontrib><creatorcontrib>Khan, M Q</creatorcontrib><creatorcontrib>Kessie, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alfaleh, F Z</au><au>Hadad, Q</au><au>Khuroo, M S</au><au>Aljumah, A</au><au>Algamedi, A</au><au>Alashgar, H</au><au>Al-Ahdal, M N</au><au>Mayet, I</au><au>Khan, M Q</au><au>Kessie, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2004-12</date><risdate>2004</risdate><volume>24</volume><issue>6</issue><spage>568</spage><epage>574</epage><pages>568-574</pages><issn>1478-3223</issn><abstract>Comparing the efficacy of peginterferon alpha-2b plus ribavirin with interferon alpha -2b plus ribavirin in Saudi patients with chronic hepatitis C virus (HCV) commonly infected with genotype 4.
A total of 96 patients with chronic HCV infection were randomly assigned to two treatment groups. Forty-eight patients received once weekly 100 microg of peginterferon alpha-2b plus ribavirin given orally 800 mg/day (peginterferon group). Another 48 patients received thrice weekly 3 million units of interferon alpha-2b plus ribavirin 800 mg/day (interferon group). At the end of treatment (48 weeks) and sustained (72 weeks) biochemical and virologic responses were determined.
In the peginterferon group, 70.8% (34/48) patients attained both biochemical and virologic responses at the end of the treatment as against 52.1% (25/48) patients in the interferon group. (P=0.09 for both). Similarly, sustained biochemical and virologic responses in the peginterferon group were attained in 52.1% (25/48) and 43.8% (21/48) patients as against 43.8% (21/48) and 29.2% (14/48) patients in the interferon group, respectively (P=0.54 and 0.20, respectively). The sustained virologic response rates in patients with genotype 4 were 42.9% (12/28) in the peginterferon group and 32.3% (10/31) in the interferon group (P=0.43). Patients in peginterferon group had higher, although statistically not significant adverse reactions.
Saudi patients with chronic HCV attained a higher, although statistically not significant sustained virologic response with pegylated interferon plus ribavirin compared with interferon plus ribavirin.</abstract><cop>United States</cop><pmid>15566506</pmid><doi>10.1111/j.1478-3231.2004.0976.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2004-12, Vol.24 (6), p.568-574 |
| issn | 1478-3223 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67135072 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Aged Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies Genotype Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - genetics Humans Interferon-alpha - administration & dosage Liver Function Tests Male Middle Aged Polyethylene Glycols Probability Recombinant Proteins Ribavirin - administration & dosage Risk Assessment RNA, Viral Saudi Arabia Severity of Illness Index Statistics, Nonparametric Treatment Outcome |
| title | Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T13%3A21%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peginterferon%20alpha-2b%20plus%20ribavirin%20compared%20with%20interferon%20alpha-2b%20plus%20ribavirin%20for%20initial%20treatment%20of%20chronic%20hepatitis%20C%20in%20Saudi%20patients%20commonly%20infected%20with%20genotype%204&rft.jtitle=Liver%20international&rft.au=Alfaleh,%20F%20Z&rft.date=2004-12&rft.volume=24&rft.issue=6&rft.spage=568&rft.epage=574&rft.pages=568-574&rft.issn=1478-3223&rft_id=info:doi/10.1111/j.1478-3231.2004.0976.x&rft_dat=%3Cproquest_pubme%3E67135072%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67135072&rft_id=info:pmid/15566506&rfr_iscdi=true |